Dynamic prediction in breast cancer: proving feasibility in clinical practice using the TEAM trial
Predictive models are an integral part of current clinical practice and help determine optimal treatment strategies for individual patients. A drawback is that covariates are assumed to have constant effects on overall survival (OS), when in fact, these effects may change during follow-up (FU). Furt...
Gespeichert in:
Veröffentlicht in: | Annals of oncology 2015-06, Vol.26 (6), p.1254-1262 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1262 |
---|---|
container_issue | 6 |
container_start_page | 1254 |
container_title | Annals of oncology |
container_volume | 26 |
creator | Fontein, D.B.Y. Klinten Grand, M. Nortier, J.W.R. Seynaeve, C. Meershoek-Klein Kranenbarg, E. Dirix, L.Y. van de Velde, C.J.H. Putter, H. |
description | Predictive models are an integral part of current clinical practice and help determine optimal treatment strategies for individual patients. A drawback is that covariates are assumed to have constant effects on overall survival (OS), when in fact, these effects may change during follow-up (FU). Furthermore, breast cancer (BC) patients may experience events that alter their prognosis from that time onwards. We investigated the ‘dynamic’ effects of different covariates on OS and developed a nomogram to calculate 5-year dynamic OS (DOS) probability at different prediction timepoints (tP) during FU.
Dutch and Belgian postmenopausal, endocrine-sensitive, early BC patients enrolled in the TEAM trial were included. We assessed time-varying effects of specific covariates and obtained 5-year DOS predictions using a proportional baselines landmark supermodel. Covariates included age, histological grade, hormone receptor and HER2 status, T- and N-stage, locoregional recurrence (LRR), distant recurrence, and treatment compliance. A nomogram was designed to calculate 5-year DOS based on individual characteristics.
A total of 2602 patients were included (mean FU 6.2 years). N-stage, LRR, and HER2 status demonstrated time-varying effects on 5-year DOS. Hazard ratio (HR) functions for LRR, high-risk N-stage (N2/3), and HER2 positivity were HR = (8.427 × 0.583tP, HR = (3.621 × 0.816tP, and HR = (1.235 × 0.851tP, respectively. Treatment discontinuation was associated with a higher mortality risk, but without a time-varying effect [HR 1.263 (0.867–1.841)]. All other covariates were time-constant.
The current nomogram accounts for elapsed time since starting adjuvant endocrine treatment and optimizes prediction of individual 5-year DOS during FU for postmenopausal, endocrine-sensitive BC patients. The nomogram can facilitate in determining whether further therapy will benefit an individual patient, although validation in an independent dataset is still needed. |
doi_str_mv | 10.1093/annonc/mdv146 |
format | Article |
fullrecord | <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_annonc_mdv146</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0923753419318162</els_id><sourcerecordid>S0923753419318162</sourcerecordid><originalsourceid>FETCH-LOGICAL-c380t-af29c3ce4e2d44f2652d879167219e3f4c513c9a09809fa77197f1e658344f1b3</originalsourceid><addsrcrecordid>eNp1kMtOwzAQRS0EoqWwZIv8AwG_8jC7qpSHVMSmrCNnMgaj1KnstFL_HlcBdqxGmnvmanQIuebsljMt74z3vYe7TbvnqjghU54XOquY4qdkyrSQWZlLNSEXMX4xxgot9DmZiLwqhJJ6SpqHgzcbB3QbsHUwuN5T52kT0MSBgvGA4T6F_d75D2rT1jWuc8PhSEHnvAPTpdykU0C6i0ds-ES6Xs5f6RCc6S7JmTVdxKufOSPvj8v14jlbvT29LOarDGTFhsxYoUECKhStUlYUuWirUvOiFFyjtApyLkEbpiumrSlLrkvLscgrmXDeyBnJxl4IfYwBbb0NbmPCoeasPrqqR1f16CrxNyO_3TUbbP_oXzkJKEcA09d7h6GO4DAZaV1AGOq2d_9UfwP7XnuF</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Dynamic prediction in breast cancer: proving feasibility in clinical practice using the TEAM trial</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Fontein, D.B.Y. ; Klinten Grand, M. ; Nortier, J.W.R. ; Seynaeve, C. ; Meershoek-Klein Kranenbarg, E. ; Dirix, L.Y. ; van de Velde, C.J.H. ; Putter, H.</creator><creatorcontrib>Fontein, D.B.Y. ; Klinten Grand, M. ; Nortier, J.W.R. ; Seynaeve, C. ; Meershoek-Klein Kranenbarg, E. ; Dirix, L.Y. ; van de Velde, C.J.H. ; Putter, H.</creatorcontrib><description>Predictive models are an integral part of current clinical practice and help determine optimal treatment strategies for individual patients. A drawback is that covariates are assumed to have constant effects on overall survival (OS), when in fact, these effects may change during follow-up (FU). Furthermore, breast cancer (BC) patients may experience events that alter their prognosis from that time onwards. We investigated the ‘dynamic’ effects of different covariates on OS and developed a nomogram to calculate 5-year dynamic OS (DOS) probability at different prediction timepoints (tP) during FU.
Dutch and Belgian postmenopausal, endocrine-sensitive, early BC patients enrolled in the TEAM trial were included. We assessed time-varying effects of specific covariates and obtained 5-year DOS predictions using a proportional baselines landmark supermodel. Covariates included age, histological grade, hormone receptor and HER2 status, T- and N-stage, locoregional recurrence (LRR), distant recurrence, and treatment compliance. A nomogram was designed to calculate 5-year DOS based on individual characteristics.
A total of 2602 patients were included (mean FU 6.2 years). N-stage, LRR, and HER2 status demonstrated time-varying effects on 5-year DOS. Hazard ratio (HR) functions for LRR, high-risk N-stage (N2/3), and HER2 positivity were HR = (8.427 × 0.583tP, HR = (3.621 × 0.816tP, and HR = (1.235 × 0.851tP, respectively. Treatment discontinuation was associated with a higher mortality risk, but without a time-varying effect [HR 1.263 (0.867–1.841)]. All other covariates were time-constant.
The current nomogram accounts for elapsed time since starting adjuvant endocrine treatment and optimizes prediction of individual 5-year DOS during FU for postmenopausal, endocrine-sensitive BC patients. The nomogram can facilitate in determining whether further therapy will benefit an individual patient, although validation in an independent dataset is still needed.</description><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdv146</identifier><identifier>PMID: 25862439</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents, Hormonal - adverse effects ; Antineoplastic Agents, Hormonal - therapeutic use ; Belgium ; Biomarkers, Tumor - analysis ; breast cancer ; Breast Neoplasms - chemistry ; Breast Neoplasms - mortality ; Breast Neoplasms - pathology ; Breast Neoplasms - therapy ; Chemotherapy, Adjuvant ; Decision Support Techniques ; dynamic prediction ; Feasibility Studies ; Female ; Humans ; landmark analysis ; Mastectomy - adverse effects ; Mastectomy - mortality ; Middle Aged ; Neoplasm Recurrence, Local ; Neoplasm Staging ; Netherlands ; Nomograms ; Patient Selection ; personalized therapy ; Predictive Value of Tests ; Receptor, ErbB-2 - analysis ; Risk Assessment ; Risk Factors ; Survival Analysis ; survival probability ; Time Factors ; Treatment Outcome</subject><ispartof>Annals of oncology, 2015-06, Vol.26 (6), p.1254-1262</ispartof><rights>2015 European Society for Medical Oncology</rights><rights>The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c380t-af29c3ce4e2d44f2652d879167219e3f4c513c9a09809fa77197f1e658344f1b3</citedby><cites>FETCH-LOGICAL-c380t-af29c3ce4e2d44f2652d879167219e3f4c513c9a09809fa77197f1e658344f1b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,27931,27932</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25862439$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fontein, D.B.Y.</creatorcontrib><creatorcontrib>Klinten Grand, M.</creatorcontrib><creatorcontrib>Nortier, J.W.R.</creatorcontrib><creatorcontrib>Seynaeve, C.</creatorcontrib><creatorcontrib>Meershoek-Klein Kranenbarg, E.</creatorcontrib><creatorcontrib>Dirix, L.Y.</creatorcontrib><creatorcontrib>van de Velde, C.J.H.</creatorcontrib><creatorcontrib>Putter, H.</creatorcontrib><title>Dynamic prediction in breast cancer: proving feasibility in clinical practice using the TEAM trial</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><description>Predictive models are an integral part of current clinical practice and help determine optimal treatment strategies for individual patients. A drawback is that covariates are assumed to have constant effects on overall survival (OS), when in fact, these effects may change during follow-up (FU). Furthermore, breast cancer (BC) patients may experience events that alter their prognosis from that time onwards. We investigated the ‘dynamic’ effects of different covariates on OS and developed a nomogram to calculate 5-year dynamic OS (DOS) probability at different prediction timepoints (tP) during FU.
Dutch and Belgian postmenopausal, endocrine-sensitive, early BC patients enrolled in the TEAM trial were included. We assessed time-varying effects of specific covariates and obtained 5-year DOS predictions using a proportional baselines landmark supermodel. Covariates included age, histological grade, hormone receptor and HER2 status, T- and N-stage, locoregional recurrence (LRR), distant recurrence, and treatment compliance. A nomogram was designed to calculate 5-year DOS based on individual characteristics.
A total of 2602 patients were included (mean FU 6.2 years). N-stage, LRR, and HER2 status demonstrated time-varying effects on 5-year DOS. Hazard ratio (HR) functions for LRR, high-risk N-stage (N2/3), and HER2 positivity were HR = (8.427 × 0.583tP, HR = (3.621 × 0.816tP, and HR = (1.235 × 0.851tP, respectively. Treatment discontinuation was associated with a higher mortality risk, but without a time-varying effect [HR 1.263 (0.867–1.841)]. All other covariates were time-constant.
The current nomogram accounts for elapsed time since starting adjuvant endocrine treatment and optimizes prediction of individual 5-year DOS during FU for postmenopausal, endocrine-sensitive BC patients. The nomogram can facilitate in determining whether further therapy will benefit an individual patient, although validation in an independent dataset is still needed.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Agents, Hormonal - adverse effects</subject><subject>Antineoplastic Agents, Hormonal - therapeutic use</subject><subject>Belgium</subject><subject>Biomarkers, Tumor - analysis</subject><subject>breast cancer</subject><subject>Breast Neoplasms - chemistry</subject><subject>Breast Neoplasms - mortality</subject><subject>Breast Neoplasms - pathology</subject><subject>Breast Neoplasms - therapy</subject><subject>Chemotherapy, Adjuvant</subject><subject>Decision Support Techniques</subject><subject>dynamic prediction</subject><subject>Feasibility Studies</subject><subject>Female</subject><subject>Humans</subject><subject>landmark analysis</subject><subject>Mastectomy - adverse effects</subject><subject>Mastectomy - mortality</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local</subject><subject>Neoplasm Staging</subject><subject>Netherlands</subject><subject>Nomograms</subject><subject>Patient Selection</subject><subject>personalized therapy</subject><subject>Predictive Value of Tests</subject><subject>Receptor, ErbB-2 - analysis</subject><subject>Risk Assessment</subject><subject>Risk Factors</subject><subject>Survival Analysis</subject><subject>survival probability</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kMtOwzAQRS0EoqWwZIv8AwG_8jC7qpSHVMSmrCNnMgaj1KnstFL_HlcBdqxGmnvmanQIuebsljMt74z3vYe7TbvnqjghU54XOquY4qdkyrSQWZlLNSEXMX4xxgot9DmZiLwqhJJ6SpqHgzcbB3QbsHUwuN5T52kT0MSBgvGA4T6F_d75D2rT1jWuc8PhSEHnvAPTpdykU0C6i0ds-ES6Xs5f6RCc6S7JmTVdxKufOSPvj8v14jlbvT29LOarDGTFhsxYoUECKhStUlYUuWirUvOiFFyjtApyLkEbpiumrSlLrkvLscgrmXDeyBnJxl4IfYwBbb0NbmPCoeasPrqqR1f16CrxNyO_3TUbbP_oXzkJKEcA09d7h6GO4DAZaV1AGOq2d_9UfwP7XnuF</recordid><startdate>201506</startdate><enddate>201506</enddate><creator>Fontein, D.B.Y.</creator><creator>Klinten Grand, M.</creator><creator>Nortier, J.W.R.</creator><creator>Seynaeve, C.</creator><creator>Meershoek-Klein Kranenbarg, E.</creator><creator>Dirix, L.Y.</creator><creator>van de Velde, C.J.H.</creator><creator>Putter, H.</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201506</creationdate><title>Dynamic prediction in breast cancer: proving feasibility in clinical practice using the TEAM trial</title><author>Fontein, D.B.Y. ; Klinten Grand, M. ; Nortier, J.W.R. ; Seynaeve, C. ; Meershoek-Klein Kranenbarg, E. ; Dirix, L.Y. ; van de Velde, C.J.H. ; Putter, H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c380t-af29c3ce4e2d44f2652d879167219e3f4c513c9a09809fa77197f1e658344f1b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Agents, Hormonal - adverse effects</topic><topic>Antineoplastic Agents, Hormonal - therapeutic use</topic><topic>Belgium</topic><topic>Biomarkers, Tumor - analysis</topic><topic>breast cancer</topic><topic>Breast Neoplasms - chemistry</topic><topic>Breast Neoplasms - mortality</topic><topic>Breast Neoplasms - pathology</topic><topic>Breast Neoplasms - therapy</topic><topic>Chemotherapy, Adjuvant</topic><topic>Decision Support Techniques</topic><topic>dynamic prediction</topic><topic>Feasibility Studies</topic><topic>Female</topic><topic>Humans</topic><topic>landmark analysis</topic><topic>Mastectomy - adverse effects</topic><topic>Mastectomy - mortality</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local</topic><topic>Neoplasm Staging</topic><topic>Netherlands</topic><topic>Nomograms</topic><topic>Patient Selection</topic><topic>personalized therapy</topic><topic>Predictive Value of Tests</topic><topic>Receptor, ErbB-2 - analysis</topic><topic>Risk Assessment</topic><topic>Risk Factors</topic><topic>Survival Analysis</topic><topic>survival probability</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fontein, D.B.Y.</creatorcontrib><creatorcontrib>Klinten Grand, M.</creatorcontrib><creatorcontrib>Nortier, J.W.R.</creatorcontrib><creatorcontrib>Seynaeve, C.</creatorcontrib><creatorcontrib>Meershoek-Klein Kranenbarg, E.</creatorcontrib><creatorcontrib>Dirix, L.Y.</creatorcontrib><creatorcontrib>van de Velde, C.J.H.</creatorcontrib><creatorcontrib>Putter, H.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fontein, D.B.Y.</au><au>Klinten Grand, M.</au><au>Nortier, J.W.R.</au><au>Seynaeve, C.</au><au>Meershoek-Klein Kranenbarg, E.</au><au>Dirix, L.Y.</au><au>van de Velde, C.J.H.</au><au>Putter, H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dynamic prediction in breast cancer: proving feasibility in clinical practice using the TEAM trial</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>2015-06</date><risdate>2015</risdate><volume>26</volume><issue>6</issue><spage>1254</spage><epage>1262</epage><pages>1254-1262</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><abstract>Predictive models are an integral part of current clinical practice and help determine optimal treatment strategies for individual patients. A drawback is that covariates are assumed to have constant effects on overall survival (OS), when in fact, these effects may change during follow-up (FU). Furthermore, breast cancer (BC) patients may experience events that alter their prognosis from that time onwards. We investigated the ‘dynamic’ effects of different covariates on OS and developed a nomogram to calculate 5-year dynamic OS (DOS) probability at different prediction timepoints (tP) during FU.
Dutch and Belgian postmenopausal, endocrine-sensitive, early BC patients enrolled in the TEAM trial were included. We assessed time-varying effects of specific covariates and obtained 5-year DOS predictions using a proportional baselines landmark supermodel. Covariates included age, histological grade, hormone receptor and HER2 status, T- and N-stage, locoregional recurrence (LRR), distant recurrence, and treatment compliance. A nomogram was designed to calculate 5-year DOS based on individual characteristics.
A total of 2602 patients were included (mean FU 6.2 years). N-stage, LRR, and HER2 status demonstrated time-varying effects on 5-year DOS. Hazard ratio (HR) functions for LRR, high-risk N-stage (N2/3), and HER2 positivity were HR = (8.427 × 0.583tP, HR = (3.621 × 0.816tP, and HR = (1.235 × 0.851tP, respectively. Treatment discontinuation was associated with a higher mortality risk, but without a time-varying effect [HR 1.263 (0.867–1.841)]. All other covariates were time-constant.
The current nomogram accounts for elapsed time since starting adjuvant endocrine treatment and optimizes prediction of individual 5-year DOS during FU for postmenopausal, endocrine-sensitive BC patients. The nomogram can facilitate in determining whether further therapy will benefit an individual patient, although validation in an independent dataset is still needed.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>25862439</pmid><doi>10.1093/annonc/mdv146</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0923-7534 |
ispartof | Annals of oncology, 2015-06, Vol.26 (6), p.1254-1262 |
issn | 0923-7534 1569-8041 |
language | eng |
recordid | cdi_crossref_primary_10_1093_annonc_mdv146 |
source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
subjects | Adult Aged Aged, 80 and over Antineoplastic Agents, Hormonal - adverse effects Antineoplastic Agents, Hormonal - therapeutic use Belgium Biomarkers, Tumor - analysis breast cancer Breast Neoplasms - chemistry Breast Neoplasms - mortality Breast Neoplasms - pathology Breast Neoplasms - therapy Chemotherapy, Adjuvant Decision Support Techniques dynamic prediction Feasibility Studies Female Humans landmark analysis Mastectomy - adverse effects Mastectomy - mortality Middle Aged Neoplasm Recurrence, Local Neoplasm Staging Netherlands Nomograms Patient Selection personalized therapy Predictive Value of Tests Receptor, ErbB-2 - analysis Risk Assessment Risk Factors Survival Analysis survival probability Time Factors Treatment Outcome |
title | Dynamic prediction in breast cancer: proving feasibility in clinical practice using the TEAM trial |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T01%3A03%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dynamic%20prediction%20in%20breast%20cancer:%20proving%20feasibility%20in%20clinical%20practice%20using%20the%20TEAM%20trial&rft.jtitle=Annals%20of%20oncology&rft.au=Fontein,%20D.B.Y.&rft.date=2015-06&rft.volume=26&rft.issue=6&rft.spage=1254&rft.epage=1262&rft.pages=1254-1262&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdv146&rft_dat=%3Celsevier_cross%3ES0923753419318162%3C/elsevier_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/25862439&rft_els_id=S0923753419318162&rfr_iscdi=true |